These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36573722)

  • 1. COVID-19 Impact on Chronic Myeloid Leukemia Patients.
    Arbore DR; Galdean SM; Dima D; Rus I; Kegyes D; Ababei RG; Dragancea D; Tomai RA; Trifa AP; Tomuleasa C
    J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36573722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
    Bonifacio M; Tiribelli M; Miggiano MC; Abruzzese E; Binotto G; Scaffidi L; Cordioli M; Damiani D; Di Bona E; Trawinska MM; Tanasi I; Dubbini MV; Velotta V; Ceccarelli G; Pierdomenico E; Lo Schirico M; Semenzato G; Ruggeri M; Fanin R; Tacconelli E; Pizzolo G; Krampera M
    Cancer Med; 2021 Sep; 10(18):6310-6316. PubMed ID: 34464516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
    Delgado N; Torres A
    Curr Oncol Rep; 2022 May; 24(5):645-650. PubMed ID: 35218499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
    Başcı S; Ata N; Altuntaş F; Yiğenoğlu TN; Dal MS; Korkmaz S; Namdaroğlu S; Baştürk A; Hacıbekiroğlu T; Doğu MH; Berber İ; Dal K; Erkurt MA; Turgut B; Çağlayan M; Ayvalı MO; Çelik O; Ülgü MM; Birinci Ş;
    J Oncol Pharm Pract; 2020 Oct; 26(7):1676-1682. PubMed ID: 32854573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study.
    Chen MT; Huang ST; Lin CW; Ko BS; Chen WJ; Huang HH; Hsiao FY
    Oncologist; 2021 Nov; 26(11):974-982. PubMed ID: 34418220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Lopina N; Dmytrenko I; Hamov D; Lopin D; Dyagil I
    Cureus; 2022 Jun; 14(6):e25766. PubMed ID: 35812557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current perspectives for the treatment of chronic myeloid leukemia.
    Aladağ E; Haznedaroğlu İC
    Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
    Chiwata M; Itonaga H; Sato S; Hashimoto M; Fujioka M; Kasai S; Sakamoto H; Toriyama E; Nakashima J; Kamijo R; Kitanosono H; Kobayashi Y; Horai M; Taguchi M; Matsuo M; Makiyama J; Takasaki Y; Matsuo E; Horio K; Ando K; Sawayama Y; Taguchi J; Kawaguchi Y; Tsushima H; Imanishi D; Imaizumi Y; Yoshida S; Jo T; Nonaka H; Moriuchi Y; Nagai K; Yokota KI; Hata T; Miyazaki Y
    Intern Med; 2021 Jul; 60(14):2207-2216. PubMed ID: 33612681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence.
    Ciftciler R; Haznedaroglu IC
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7787-7798. PubMed ID: 34982440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption.
    Demeter J; Weisinger J; Nagy Z
    Mediterr J Hematol Infect Dis; 2021; 13(1):e2021022. PubMed ID: 33747403
    [No Abstract]   [Full Text] [Related]  

  • 14. Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2.
    Galimberti S; Petrini M; Baratè C; Ricci F; Balducci S; Grassi S; Guerrini F; Ciabatti E; Mechelli S; Di Paolo A; Baldini C; Baglietto L; Macera L; Spezia PG; Maggi F
    Front Oncol; 2020; 10():1428. PubMed ID: 33014780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
    Kong JH; Winton EF; Heffner LT; Gaddh M; Hill B; Neely J; Hatcher A; Joseph M; Arellano M; El-Rassi F; Kim A; Khoury JH; Kota VK
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32443762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.
    Iriyama N; Tokuhira M; Takaku T; Sato E; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Fujioka I; Hatta Y; Kizaki M; Komatsu N; Asou N; Kawaguchi T
    Leuk Res; 2017 Mar; 54():55-58. PubMed ID: 28109974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
    Haznedaroğlu İC; Kuzu I; İlhan O
    Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.